Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401169 | 0.82 | CARM1 (0.52) | MEN1KMT2ACARM1PRMT6NPSR1 | |
| SCHEMBL28961482 | 0.79 | USP30 (0.54) | MEN1KMT2AUSP30NPSR1NPC1 | |
| SCHEMBL3099776 | 0.79 | MEN1 (0.44) | MEN1KMT2ACARM1PRMT6USP30 | |
| SCHEMBL3105144 | 0.78 | HRH3 (0.47) | MEN1KMT2ACARM1PRMT6NPSR1 | |
| SCHEMBL2399783 | 0.77 | NPSR1 (0.49) | MEN1KMT2ACARM1PRMT6NPSR1 | |
| SCHEMBL2400798 | 0.77 | ALDH1A1 (0.47) | MEN1KMT2ACARM1PRMT6PREP | |
| SCHEMBL2399591 | 0.77 | POLB (0.45) | MEN1KMT2ACARM1PRMT6NPSR1 | |
| SCHEMBL2402365 | 0.74 | NPSR1 (0.46) | CARM1PRMT6PREPFAPNPSR1 | |
| SCHEMBL16219443 | 0.74 | MEN1 (0.64) | MEN1KMT2ACARM1PRMT6NPSR1 | |
| SCHEMBL27604695 | 0.74 | DPP7 (0.48) | MEN1KMT2ANPSR1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | disclosed |
| US-8431540-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2012-09-27 | — | — | US | disclosed |
| US-8026272-B2 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2011-09-27 | — | — | US | disclosed |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S and Wyeth | 2010-09-30 | — | — | US | disclosed |
| US-7622496-B2 | antiarrhythmia agents; 1-(2-Amino-acetyl)-4-(benzoylamino)-pyrrolidine-2-carboxylic acid; desirable bioavailability properties | ZEALAND PHARMA A/S (DK) | 2009-11-24 | — | — | US | disclosed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245106-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885CARM1 402/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885CARM1 402/4885 |
| US-20100249206-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885CARM1 402/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MEN1 1114/4885KMT2A 89/4885CARM1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.